• Explore /
  • Poster
  • / A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

Abstract Poster

Authors

null

Jonathan W. Riess

University of California Davis Comprehensive Cancer Center, Sacramento, CA

Jonathan W. Riess , Mary Weber Redman , Paul Wheatley-Price , Bryan A. Faller , Liza C. Villaruz , Larry R. Corum , Aruna C. Gowda , Gordan Srkalovic , Raymond U. Osarogiagbon , Megan Ann Baumgart , Lu Qian , Katherine Minichiello , David R. Gandara , Roy S. Herbst , Karen Kelly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03845296

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9024)

DOI

10.1200/JCO.2021.39.15_suppl.9024

Abstract #

9024

Abstract Disclosures

Similar Posters

First Author: Kim Anna Reiss

First Author: Kim Anna Reiss

Poster

2023 ASCO Annual Meeting

HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).

HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).

First Author: June Evelyn Jeon

First Author: Kim Anna Reiss